Both Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Table 1 demonstrates Ampio Pharmaceuticals Inc. and Conatus Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 represents Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s return on equity, net margins and return on assets.

Risk & Volatility

A beta of 0.85 shows that Ampio Pharmaceuticals Inc. is 15.00% less volatile than S&P 500. Conatus Pharmaceuticals Inc.’s 120.00% more volatile than S&P 500 which is a result of the 2.2 beta.

Liquidity

Ampio Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 3.7 and 3.7 respectively. The Current Ratio and Quick Ratio of its competitor Conatus Pharmaceuticals Inc. are 2.4 and 2.4 respectively. Ampio Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Conatus Pharmaceuticals Inc.

Institutional & Insider Ownership

The shares of both Ampio Pharmaceuticals Inc. and Conatus Pharmaceuticals Inc. are owned by institutional investors at 33.8% and 25.1% respectively. 10.71% are Ampio Pharmaceuticals Inc.’s share owned by insiders. Competitively, insiders own roughly 3.34% of Conatus Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Ampio Pharmaceuticals Inc. has stronger performance than Conatus Pharmaceuticals Inc.

Summary

On 11 of the 11 factors Ampio Pharmaceuticals Inc. beats Conatus Pharmaceuticals Inc.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.